CATX
Perspective Therapeutics Inc.
2.50$
+0.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2019 | 2020 | 2020 | 2021 | 2021 | 2022 | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 77.6% | 63.3% | 63.3% | 79.2% | 95.6% | 92.1% | 92.1% | 91.6% | 91.6% | 17.2% | 67.8% | 55.6% | |
| 56.5% | 27.5% | 27.5% | 61.8% | 90.6% | 86.7% | 86.7% | 36.1% | 36.1% | 9.4% | 18.1% | 11.5% | |
| 56.5% | 27.5% | 27.5% | 61.8% | 90.6% | – | 86.7% | 75.3% | 75.3% | 9.4% | 66.5% | 54.2% | |
| 12.2% | 23.5% | 23.5% | 11.2% | 2.9% | 2.5% | 2.5% | 2.3% | 2.3% | 1.2% | 0.0% | 0.4% | |
| 5.6% | 7.4% | 7.4% | 4.3% | 1.4% | 2.2% | 2.2% | 2.4% | 2.4% | – | – | – | |
| – | – | 31.5% | – | 3.9% | – | 3.9% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | 24.6% | 0.0% | – | |
| 1.7% | 1.6% | 1.6% | 0.8% | 0.2% | 0.2% | 0.2% | 0.0% | 0.1% | 51.4% | 14.7% | 15.0% | |
| 18.5% | 34.2% | 34.2% | 17.7% | 4.3% | 4.9% | 4.9% | 5.9% | 5.9% | 23.2% | 14.8% | 22.5% | |
| 11.9% | 18.1% | 18.1% | 8.6% | 2.6% | 3.5% | 3.5% | 5.4% | 4.6% | 16.0% | 5.3% | 10.7% | |
| – | 2.7% | 2.7% | 1.6% | 0.4% | – | 0.4% | 0.5% | – | 0.1% | 0.3% | 0.3% | |
| 7.2% | 7.5% | 7.5% | 3.2% | 1.0% | 1.5% | 1.5% | 2.7% | 2.7% | 7.1% | 3.0% | 7.7% | |
| – | – | – | – | – | – | – | – | – | 1.7% | 0.5% | 0.6% | |
| 81.5% | 65.8% | 65.8% | 82.3% | 95.7% | 95.1% | 95.1% | 94.1% | 94.1% | 76.8% | 85.2% | 77.5% | |
| -896.8% | -1,010.9% | -1,010.9% | -577.1% | -129.7% | -153.0% | -153.0% | -182.4% | -182.4% | -155.7% | -67.9% | -125.4% | |
| 711.5% | 777.1% | 777.1% | 353.9% | 147.5% | 22.0% | 220.3% | 24.5% | 244.6% | 56.1% | 18.9% | 27.6% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.